SLC5A2 and chronic kidney disease: Our base case analysis relied on data from a single randomized clinical trial, DAPA-CKD.2 Although other clinical trials have tested the efficacy of SGLT2 inhibitors in CKD, these trial populations have differed in that they have included patients with and without albuminuria (EMPA-KIDNEY)3 or included only patients with diabetes (CREDENCE, SCORED),58,59 which precluded us from directly incorporating these trial results in our model.